Related Experiment Video

Updated: May 22, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells

E Pestereva1, S Kanakasabai, J J Bright

  • 1Neuroscience Research Laboratory, Methodist Research Institute, Indiana University Health, 1800 North Capitol Avenue, Noyes Building E504C, Indianapolis, IN 46202, USA.

British Journal of Cancer
|April 26, 2012
PubMed
Abstract

Insights

Peroxisome proliferator-activated receptor gamma (PPARγ) agonists reduce brain tumour stem cell (BTSC) proliferation and alter stemness gene expression. Targeting these stemness genes offers a potential glioblastoma treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Stem Cell Research

Background:

  • Brain tumour stem cells (BTSCs) drive glioma recurrence and drug resistance.
  • Previous studies indicated peroxisome proliferator-activated receptor gamma (PPARγ) agonists inhibit BTSC expansion.
  • This study investigates the impact of PPARγ agonists on BTSC stemness and differentiation genes.

Purpose of the Study:

  • To analyze the effect of PPARγ agonists on stemness and differentiation gene expression in BTSCs.
  • To evaluate the potential of PPARγ agonists as a therapeutic strategy for glioblastoma.

Main Methods:

  • Isolation and culture of BTSCs from T98G and DB29 glioma cells.
  • Assessment of cell proliferation using WST-1 and 3H thymidine uptake assays.
  • Analysis of gene expression (CD133, Sox2, Nanog) via qRT-PCR, Western blotting, immunostaining, and flow cytometry.

Main Results:

  • PPARγ agonists (ciglitazone, 15d-PGJ2) inhibited BTSC viability and proliferation.
  • PPARγ agonists reduced CD133+ BTSC expansion.
  • PPARγ agonists modulated stemness genes, inhibiting Sox2 and enhancing Nanog expression.

Conclusions:

  • PPARγ agonists suppress BTSC proliferation by altering key stemness genes like Sox2 and Nanog.
  • Targeting stemness genes in BTSCs represents a promising therapeutic approach for glioblastoma treatment.

More Related Videos

Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells09:24

Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells

Published on: May 9, 2020

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...